Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer

Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer

Poly(ADP-ribose) polymerase inhibitors (PARPi) are FDA approved as frontline maintenance for BRCA-associated advanced stage high-grade ovarian cancer (HGOC), having demonstrated an unprecedented improvement in relapse-free survival. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are...

Full description

Saved in:
Bibliographic Details
Main Authors: Anastasia Navitski (Author), Duaa H. Al-Rawi (Author), Ying Liu (Author), Maria M. Rubinstein (Author), Claire F. Friedman (Author), Raajit K. Rampal (Author), Diana L. Mandelker (Author), Karen Cadoo (Author), Roisin E. O'Cearbhaill (Author)
Format: Book
Published: Elsevier, 2021-11-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items